These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11672925)

  • 1. Marburg virus vaccines: comparing classical and new approaches.
    Hevey M; Negley D; VanderZanden L; Tammariello RF; Geisbert J; Schmaljohn C; Smith JF; Jahrling PB; Schmaljohn AL
    Vaccine; 2001 Nov; 20(3-4):586-93. PubMed ID: 11672925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
    Hevey M; Negley D; Pushko P; Smith J; Schmaljohn A
    Virology; 1998 Nov; 251(1):28-37. PubMed ID: 9813200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants.
    Hevey M; Negley D; Geisbert J; Jahrling P; Schmaljohn A
    Virology; 1997 Dec; 239(1):206-16. PubMed ID: 9426460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
    Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
    Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.
    Mellquist-Riemenschneider JL; Garrison AR; Geisbert JB; Saikh KU; Heidebrink KD; Jahrling PB; Ulrich RG; Schmaljohn CS
    Virus Res; 2003 Apr; 92(2):187-93. PubMed ID: 12686428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
    Swenson DL; Warfield KL; Negley DL; Schmaljohn A; Aman MJ; Bavari S
    Vaccine; 2005 Apr; 23(23):3033-42. PubMed ID: 15811650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes.
    Hevey M; Negley D; Schmaljohn A
    Virology; 2003 Sep; 314(1):350-7. PubMed ID: 14517087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.
    Warfield KL; Swenson DL; Negley DL; Schmaljohn AL; Aman MJ; Bavari S
    Vaccine; 2004 Sep; 22(25-26):3495-502. PubMed ID: 15308377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.
    Swenson DL; Warfield KL; Larsen T; Alves DA; Coberley SS; Bavari S
    Expert Rev Vaccines; 2008 May; 7(4):417-29. PubMed ID: 18444889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever.
    Sun Y; Li HY; Tian DY; Han QY; Zhang X; Li N; Qiu HJ
    Vaccine; 2011 Oct; 29(46):8364-72. PubMed ID: 21888938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
    Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
    Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
    Jones SM; Feldmann H; Ströher U; Geisbert JB; Fernando L; Grolla A; Klenk HD; Sullivan NJ; Volchkov VE; Fritz EA; Daddario KM; Hensley LE; Jahrling PB; Geisbert TW
    Nat Med; 2005 Jul; 11(7):786-90. PubMed ID: 15937495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges.
    Wang D; Hevey M; Juompan LY; Trubey CM; Raja NU; Deitz SB; Woraratanadharm J; Luo M; Yu H; Swain BM; Moore KM; Dong JY
    Virology; 2006 Sep; 353(2):324-32. PubMed ID: 16820184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.
    Mühlberger E; Lötfering B; Klenk HD; Becker S
    J Virol; 1998 Nov; 72(11):8756-64. PubMed ID: 9765419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.
    Riemenschneider J; Garrison A; Geisbert J; Jahrling P; Hevey M; Negley D; Schmaljohn A; Lee J; Hart MK; Vanderzanden L; Custer D; Bray M; Ruff A; Ivins B; Bassett A; Rossi C; Schmaljohn C
    Vaccine; 2003 Sep; 21(25-26):4071-80. PubMed ID: 12922144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus.
    Pujhari S; Baig TT; Hansra S; Zakhartchouk AN
    Virus Res; 2013 May; 173(2):321-6. PubMed ID: 23353778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.
    Grant-Klein RJ; Altamura LA; Schmaljohn CS
    Virus Res; 2011 Dec; 162(1-2):148-61. PubMed ID: 21925552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the cell-mediated immunity induced by alphavirus replicon-vectored DNA vaccines against classical swine fever in a mouse model.
    Zhao HP; Sun JF; Li N; Sun Y; Xia ZH; Wang Y; Cheng D; Qi QF; Jin ML; Qiu HJ
    Vet Immunol Immunopathol; 2009 May; 129(1-2):57-65. PubMed ID: 19150136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.